![ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo](/.imaging/default/dam/Marketing/AltuviiioUS/altuviiio.webp/jcr:content.webp)
Meet Natalie and Samuel
“Samuel was adopted from China when he was 4 and a half years old. When his dad and I first saw the pictures in his adoption file, he had a black eye and a goose egg on his head. The adoption agency suspected hemophilia, but he was never officially tested. When we traveled to China to meet Samuel, he was in a lot of pain and could barely walk. We arrived home to Ohio on a Friday. The following Monday, he was diagnosed with severe hemophilia A, and we got him started on a prophy treatment. That was a long 8-hour day, but it’s also how we met our hematologist—she’s wonderful.
As Samuel grew up, it became clear we needed a treatment that would protect him from bleeds and also allow him to stay busy. That’s why we were so interested when our hematologist told us about ALTUVIIIO and its fewer infusions. She shared that ALTUVIIIO is the only once-weekly prophylaxis Factor VIII replacement therapy. ALTUVIIIO’s higher factor levels were associated with lower bleed risk, and the once-weekly dosing would allow us to schedule our weeks around fewer infusion times.
We felt great about switching to ALTUVIIIO. Transitioning was also easy, especially with the assistance of our Case Manager and our CoRe (Community Resource and Education) Manager. Today, we are living with a treatment and schedule that works for us. Our dosing schedule is Saturdays. Samuel likes that he has more time for activities and hanging out with friends—he’s getting the most out of being a kid.”
Natalie and Samuel are promotional speakers compensated by Sanofi. Peer stories based on data collected March 2026.
Get an overview of all the Peers in our network here!
Sign up for the Peer Mentor Program
Connect with a real ALTUVIIIO patient or caregiver for advice, information about their
experience, and more.
Hear from more patients
A well-traveled, local theater actor who switched from an EHL to ALTUVIIIO in 2023.
A critical care nurse, and advocate for other women with hemophilia, who switched to ALTUVIlIO in 2023.
A woman with hemophilia A who switched from on-demand therapy to ALTUVIIIO prophylaxis in May 2023.
ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
Your healthcare provider may give you ALTUVIIIO when you have surgery.
What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.
Who should not use ALTUVIIIO?
You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.
What should I tell my healthcare provider before using ALTUVIIIO?
Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.
What are the possible side effects of ALTUVIIIO?
You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called “inhibitors” against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.
The common side effects of ALTUVIIIO are headache and joint pain.
These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.
Please see full Prescribing Information.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
![ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] logo](/dam/jcr:0bd6aa08-1390-4c29-8440-7d6809e35b97/Altuviiio.svg)